| CEO Name | Robert A. Bradway |
| Nationality | United States |
| Net Worth Estimation | $140 million |
Robert A. Bradway, CEO of Amgen Inc., has amassed an estimated net worth of around $140 million primarily through his long-term executive compensation, bonuses, stock awards, and stock options at Amgen. This valuation combines his annual salary, performance-based incentives, and substantial equity holdings accrued since joining Amgen in 2006 and becoming CEO in 2012.
Robert A. Bradway's estimated net worth of $140,000,000 is about 55.6% higher than the highest benchmark ($90,000,000) for CEOs in the healthcare business category. His wealth also surpasses the minimum benchmark ($10,000,000) by 1,300%.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
Robert A. Bradway Performance in Amgen Inc.
Robert A. Bradway, CEO of Amgen Inc., exemplifies strategic leadership and data-driven decision making, fostering innovation in biotechnology. Under his guidance, Amgen has expanded its product portfolio and global reach, significantly boosting financial performance and shareholder value. Bradway's focus on pipeline development and operational efficiency has driven sustainable growth and solidified Amgen's position as a leading biopharmaceutical company.
Latest News
Amgen Inc. Reports Strong Q3 2025 Growth and Strategic Investments
Amgen CEO Robert A. Bradway highlighted robust volume growth, increased free cash flow, and a 12% rise in total revenues, driven by global demand for innovative medicines and disciplined investments. The company also announced major U.S. manufacturing expansions and a new $600 million science and innovation center, reinforcing its commitment to long-term growth and scientific advancement.
Source: http://www.prnewswire.com/news-releases/amgen-reports-third-quarter-2025-financial-results-302604667.html